Siegfried Köhler
YOU?
Author Swipe
View article: POLAR: prediction of prolonged mechanical ventilation in patients with myasthenic crisis
POLAR: prediction of prolonged mechanical ventilation in patients with myasthenic crisis Open
View article: Opposite Regulation of Homer Signal at the NMJ Postsynaptic Micro Domain between Slow- and Fast-Twitch Muscles in an Experimentally Induced Autoimmune Myasthenia Gravis (EAMG) Mouse Model
Opposite Regulation of Homer Signal at the NMJ Postsynaptic Micro Domain between Slow- and Fast-Twitch Muscles in an Experimentally Induced Autoimmune Myasthenia Gravis (EAMG) Mouse Model Open
Accelerated postsynaptic remodelling and disturbance of neuromuscular transmission are common features of autoimmune neurodegenerative diseases. Homer protein isoform expression, crosslinking activity and neuromuscular subcellular localisa…
View article: Early recognition and treatment of pre-VITT syndrome after adenoviral vector-based SARS-CoV-2 vaccination may prevent from thrombotic complications: review of published cases and clinical pathway
Early recognition and treatment of pre-VITT syndrome after adenoviral vector-based SARS-CoV-2 vaccination may prevent from thrombotic complications: review of published cases and clinical pathway Open
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but highly morbid complication after adenoviral vector-based SARS-CoV-2 vaccination. The pre-VITT syndrome is defined as vaccine-induced immune thrombocytopenia without th…
View article: Seronegative myasthenic crisis: a multicenter analysis
Seronegative myasthenic crisis: a multicenter analysis Open
Myasthenic crisis (MC) is a life-threatening condition for patients with myasthenia gravis (MG). Seronegative patients represent around 10–15% of MG, but data on outcome of seronegative MCs are lacking. We performed a subgroup analysis of …
View article: Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial Open
View article: MuSK-antibodies are associated with worse outcome in myasthenic crisis requiring mechanical ventilation
MuSK-antibodies are associated with worse outcome in myasthenic crisis requiring mechanical ventilation Open
Myasthenic crisis (MC) is a life-threatening condition for patients with myasthenia gravis (MG). Muscle-specific kinase-antibodies (MuSK-ABs) are detected in ~ 6% of MG, but data on outcome of MuSK-MCs are still lacking. We made a subgroup…
View article: Untersuchungen zur Pathophysiologie und zu experimentellen Therapieansätzen der Myasthenia Gravis
Untersuchungen zur Pathophysiologie und zu experimentellen Therapieansätzen der Myasthenia Gravis Open
Die autoimmune Myasthenia Gravis ist eine seit vielen Jahren bekannte und in ihrer pathophysiologischen Endstrecke relativ gut charakterisierte antikörpervermittelte Autoimmunerkrankung. Es ist jedoch weiterhin unklar, wie das komplexe Zus…
View article: Calprotectin as potential novel biomarker in myasthenia gravis
Calprotectin as potential novel biomarker in myasthenia gravis Open
Myasthenia gravis (MG) is the most common autoimmune disease affecting the neuromuscular junction by specific autoantibodies. The etiology of MG and its heterogeneity in clinical courses are poorly understood, although it was recently show…
View article: Early Tracheostomy Is Associated With Shorter Ventilation Time and Duration of ICU Stay in Patients With Myasthenic Crisis—A Multicenter Analysis
Early Tracheostomy Is Associated With Shorter Ventilation Time and Duration of ICU Stay in Patients With Myasthenic Crisis—A Multicenter Analysis Open
Background: Myasthenic crisis (MC) requiring mechanical ventilation (MV) is a rare and serious complication of myasthenia gravis. Here we analyzed the frequency of performed tracheostomies, risk factors correlating with a tracheostomy, as …
View article: Bortezomib at therapeutic doses poorly passes the blood–brain barrier and does not impair cognition
Bortezomib at therapeutic doses poorly passes the blood–brain barrier and does not impair cognition Open
The 26S proteasome inhibitor bortezomib is currently used to treat multiple myeloma but also is effective in the treatment of antibody-mediated autoimmune disorders. One clinical concern is bortezomib’s toxicity towards the (central) nervo…
View article: Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial
Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial Open
Introduction The clinical characteristics of autoantibody-mediated autoimmune diseases are diverse. Yet, medical treatment and the associated complications are similar, that is, the occurrence of long-term side effects and the problem that…
View article: Thymectomy in Myasthenia Gravis
Thymectomy in Myasthenia Gravis Open
In recent years much progress has been made in the investigation of the pathophysiology, characterizing subgroups, and extension of multimodal treatment of myasthenia gravis (MG). This applies especially to the role of thymectomy (Thx). Th…
View article: The Lambert-Eaton Myasthenic Syndrome — an Overview
The Lambert-Eaton Myasthenic Syndrome — an Overview Open
The Lambert Eaton myasthenic syndrome (LEMS) has a prevalence of around 5/100 0000 and is around 10–20 times rarer than myasthenia gravis (MG). Although LEMS does have a number of similarities to MG, there are important differences. The sy…
View article: Myasthenia gravis: subgroup classifications
Myasthenia gravis: subgroup classifications Open
View article: Quantitative motor assessment of muscular weakness in myasthenia gravis: a pilot study
Quantitative motor assessment of muscular weakness in myasthenia gravis: a pilot study Open
Q-Motor tests and particularly QIMA may be useful objective tools for measuring motor impairment in MG and seem to detect subclinical generalized motor signs in patients with OMG. Q-Motor parameters might serve as sensitive endpoints for c…
View article: IL‐17‐producing CD4 <sup>+</sup> T cells contribute to the loss of B‐cell tolerance in experimental autoimmune myasthenia gravis
IL‐17‐producing CD4 <sup>+</sup> T cells contribute to the loss of B‐cell tolerance in experimental autoimmune myasthenia gravis Open
The role of Th17 cells in the pathogenesis of autoantibody‐mediated diseases is unclear. Here, we assessed the contribution of Th17 cells to the pathogenesis of experimental autoimmune myasthenia gravis (EAMG), which is induced by repetiti…